Oragenics Activates Full Australian Trial Network for Concussion Drug — Oragenics, Inc.

Event summary

All three Australian Phase IIa trial sites for ONP-002 are now active, with Royal Adelaide Hospital receiving final approval on June 29, 2026.
Alfred Health enrolled the first participant in the trial on June 21, 2026.
Oragenics submitted a Type B meeting request to the FDA on June 26, 2026, to advance the U.S. regulatory pathway for ONP-002.
No serious adverse events have been reported across all subjects dosed to date.

The big picture

Oragenics' full activation of its Australian Phase IIa trial network marks a critical milestone in the development of ONP-002, a first-in-class intranasal neurosteroid for treating concussions. The company's parallel progress in engaging with the FDA underscores its strategic push to bring a novel therapeutic to a market currently devoid of pharmacological treatments. Success here could position Oragenics as a key player in the neurological drug space, leveraging its proprietary intranasal delivery technology.

What we're watching

Trial Execution: The pace at which Oragenics can enroll participants and generate Phase IIa data readout in Q4 2026.
Regulatory Pathway: How the FDA's response to the Type B meeting request will shape the U.S. clinical development program for ONP-002.
Market Opportunity: Whether Oragenics can capitalize on the lack of FDA-approved treatments for mild traumatic brain injury (mTBI).